Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CRAT | P43155 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 11/20 | 0.34 |
| ▸ | CA2 | P00918 | 11/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL27500714 | 0.99 | SLC22A16 (0.56) | SLC22A16MAPTCPT2CPT1ANOS3 | |
| Carnitine SCHEMBL15322671 | 0.96 | SLC22A16 (0.53) | SLC22A16MAPTCPT2CPT1ANOS3 | |
| Carnitine SCHEMBL27500124 | 0.95 | SLC22A16 (0.51) | SLC22A16MAPTCPT2CPT1ANOS3 | |
| Carnitine SCHEMBL3651733 | 0.82 | SLC22A16 (0.39) | SLC22A16MAPT | |
| Fosfocreatine SCHEMBL4277995 | 0.80 | SLC22A16 (0.50) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Propionyl-Carnitine SCHEMBL4279796 | 0.80 | MEN1 (0.65) | MAPTCPT2CPT1AMEN1KMT2A | |
| Creatine SCHEMBL5422993 | 0.80 | MEN1 (0.41) | SLC22A16MAPTCPT2CPT1ANOS3 | |
| Fosfocreatine SCHEMBL4277999 | 0.79 | SLC22A16 (0.49) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Creatine SCHEMBL4137956 | 0.78 | NOS3 (0.41) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL15322407 | 0.78 | MEN1 (0.45) | SLC22A16MAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567705-A2 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | Avicena Group, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2006-10-26 | — | — | US | claimed |
| EP-1567180-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | Avicena Group, Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | CINCINNATI, UNIVERSITY OF | 2004-07-01 | — | — | US | claimed |
| WO-2003101402-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | AVICENA GROUP, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| CN-108719692-A | A kind of Snakeheaded fish feeding stuff, preparation method and the cultural method of crisp meat snakehead | 王会清 | 2018-11-02 | — | — | CN | disclosed |
| CN-104703583-A | Modified hyaluronic acid derivatives and uses thereof | SIGMA TAU IND FARMACEUTI | 2015-06-10 | — | — | CN | disclosed |
| EP-2567705-A2 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | Avicena Group, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120245211-A1 | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-09-27 | — | — | US | disclosed |
| US-20090221706-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI | 2009-09-03 | — | — | US | disclosed |
| US-20070027090-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI | 2007-02-01 | — | — | US | disclosed |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2006-10-26 | — | — | US | disclosed |
| EP-1567180-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | Avicena Group, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | CINCINNATI, UNIVERSITY OF | 2004-07-01 | — | — | US | disclosed |
| WO-2003101402-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | AVICENA GROUP, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027090-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | SLC22A16 978/4885MAPT 352/4885CPT2 15/4885 |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | SLC22A16 978/4885MAPT 352/4885CPT2 15/4885 |
| US-20120245211-A1 | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism | PC, PYGB, PCK2 | SLC22A16 978/4885MAPT 352/4885CPT2 15/4885 |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | SLC22A16 978/4885MAPT 352/4885CPT2 15/4885 |
| US-20090221706-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | SLC22A16 978/4885MAPT 352/4885CPT2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.